An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease
- First Posted Date
- 2009-11-16
- Last Posted Date
- 2011-03-15
- Lead Sponsor
- Link Medicine Corporation
- Target Recruit Count
- 110
- Registration Number
- NCT01013610
- Locations
- 🇺🇸
St. Louis Clinical Trials, LC, St. Louis, Missouri, United States
🇺🇸Collaborative Neuroscience Network, Long Beach, California, United States
🇺🇸Dedicated Phase I, Phoenix, Arizona, United States
A Double-Blind, Placebo Controlled, Single, Escalating Dose Study to Evaluate the Preliminary Pharmacokinetics, Safety and Tolerability of LNK-754 in Healthy Elderly Volunteers
Phase 1
Completed
- Conditions
- Healthy Elderly Volunteers
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2009-09-10
- Lead Sponsor
- Link Medicine Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT00903253
- Locations
- 🇺🇸
CEDRA Clinical Research, Austin, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath